Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Our Products
MouseAtlas
iPSC Cell Lines
Knockout Cell Lines
Tumor Cell Lines
Adeno-associated Virus (AAV) Standard Capsid
Featured Catalog
Humanized Mouse Models
HUGO-GT™
HUGO-Ab™
Humanized Target Gene Models
Humanized Immune System Mouse Models
Tool Mice
Cre Mouse Lines
Disease Models
Autoimmune Disease Models
Ophthalmic Disease Models
Immunodeficient Mouse Models
Metabolic Disease Models
Neurological Disease Models
Oncology & Immuno-oncology Models
Services
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Genetically Engineered Animals
Knockin Mice
Knockin Rats
Knockout Mice
Knockout Rats
Transgenic Mice
Transgenic Rats
Transgenic Model Generation
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Adenovirus Packaging
Lentivirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Overexpression Cell Lines
Point Mutation Cell Lines
Breeding & Supporting Services
BAC Modification
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
Drug Discovery and Development
Antibody Discovery Platform
HUGO-Ab™
HUGO-Mab™
HUGO-Light™
HUGO-Nano™
HUGO-Ab-eKO™
Therapeutic Area
Neurology
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Blood Brain Barrier (BBB)
Metabolic & Cardiovascular
Obesity
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Oncology
PBMC Humanized Mouse Model
Human Immune System (HIS) Mouse Model
Immunology & Inflammation
Asthma
Innovative Drug R&D
Therapeutic Antibody Drugs
Monoclonal Antibodies (mAb)
Bispecific Antibodies (BsAb)
ADC/AOC
AI-Powered AAV Discovery
Cell Immunotherapy
Gene Therapy
Oligonucleotide Therapy
Fully Human Antibody Library
Neurology Antibodies
Metabolic & Cardiovascular Antibodies
Ophthalmology Antibodies
Oncology Antibodies
Immunology & Inflammation Antibodies
Resources
News
Blogs & Insight
Promotion
Events & Webinars
Databases
AbSeek
Rare Disease Data Center
Cell iGeneEditor™ System
Citations
Resource Vault
OriCell
About Us
Animal Health & Welfare
Corporate Overview
Facility Overview
Our Team
Our Partners
Careers
Health Reports
Contact Us
Login
FILTERS
FILTERS
KO/cKO Mouse Models
Flash Sales
HUGO-GT™ Platform
Full-Gene Humanized Models
Humanized Target Gene Models
Immune Target Humanized ModelsTumor Target Humanized ModelsMetabolic Target Humanized ModelsCytokine Humanized ModelsOther Target Humanized Models
Immune System Mouse Models
Immunodeficient Mouse ModelsHumanized Immune System Models
Genetic Tool Mouse Models
Cre Driver LinesReporter Mouse LinesOther Genetic Tool Lines
Specialized Disease Models
Ophthalmic Disease ModelsNeurological Disease ModelsMetabolic Disease ModelsOncology & Immuno-oncology ModelsAutoimmune Disease ModelsRare Disease ModelsInfectious Disease ModelsOther Disease Models
8 Results Retrieved With“Other Genetic Tool Lines”
Filter
Sort By:
Alphabetical (A-Z)
Best Sellers
Cd7-Furin-GSG-T2A-Dre
Product ID:
I001084
Strain:
C57BL/6JCya
Status:
Live Mouse
Description:
The TGA stop codon of the mouse Cd7 gene is replaced with Furin-GSG-T2A-Dre. The Furin sequence helps to remove the 2A residues from the upstream protein, while the GSG linkers can provide the necessary space to ensure proper protein folding and self-cleavage of the 2A sequence.
The TGA stop codon of the mouse Cd7 gene is replaced with Furin-GSG-T2A-Dre. The Furin sequence helps to remove the 2A residues from the upstream protein, while the GSG linkers can provide the necessary space to ensure proper protein folding and self-cleavage of the 2A sequence.
Cd34-Dre
Product ID:
I001068
Strain:
C57BL/6JCya
Status:
Live Mouse
Description:
For the Kl model, the coding sequence of the exon 1 plus partial intron 1 was replaced with the Dre-rBG pA cassette. This model expresses Dre recombinase driven by the regulatory elements of the mouse Cd34 gene.
For the Kl model, the coding sequence of the exon 1 plus partial intron 1 was replaced with the Dre-rBG pA cassette. This model expresses Dre recombinase driven by the regulatory elements of the mouse Cd34 gene.
Cd68-loxP-Stop-loxP-DTR
Product ID:
C001750
Strain:
C57BL/6JCya
Status:
Live Mouse
Description:
The loxP-3*SV40 pA-loxP-IRES-DTR-rBG pA cassette was inserted downstream of the TGA stop codon. Upstream of the DTR (diphtheria toxin receptor) gene lies a loxP-Stop-loxP cassette that blocks DTR transcription and expression. Upon Cre recombination, Cre-mediated deletion of the loxP-flanked stop (LSL) element enables DTR expression in Cre-positive cells. Intravenous administration of diphtheria toxin (DT) then selectively ablates these cells.
The loxP-3*SV40 pA-loxP-IRES-DTR-rBG pA cassette was inserted downstream of the TGA stop codon. Upstream of the DTR (diphtheria toxin receptor) gene lies a loxP-Stop-loxP cassette that blocks DTR transcription and expression. Upon Cre recombination, Cre-mediated deletion of the loxP-flanked stop (LSL) element enables DTR expression in Cre-positive cells. Intravenous administration of diphtheria toxin (DT) then selectively ablates these cells.
H11-CAG-hCas
Product ID:
C001827
Strain:
C57BL/6JCya
Status:
Live Mouse
Description:
The CRISPR/Cas system has revolutionized genome editing by enabling precise and efficient genetic modifications in vivo [1-2]. This system consists of two principal components: the CRISPR-associated (Cas) endonucleases, which introduces site-specific double-strand breaks in DNA, and a guide RNA (gRNA), a short RNA sequence embedded within a scaffold that directs Cas to its genomic target via sequence complementarity [3]. H11-CAG-hCas mice carry a human codon-optimized Streptococcus pyogenes CRISPR-associated protein 9 (SpCas9) expression cassette, driven by the ubiquitous CAG promoter. This configuration ensures systemic expression of Cas protein across tissues. Notably, constitutive Cas expression in these mice does not elicit detectable toxicity, morphological abnormalities, tumorigenesis, or activation of DNA damage or apoptotic pathways. In the presence of sequence-specific single-guide RNAs (sgRNAs), this model enables efficient and simultaneous editing of single or multiple genes. H11-CAG-hCas mice are viable, fertile, and well-suited for a wide range of genome engineering applications.
The CRISPR/Cas system has revolutionized genome editing by enabling precise and efficient genetic modifications in vivo [1-2]. This system consists of two principal components: the CRISPR-associated (Cas) endonucleases, which introduces site-specific double-strand breaks in DNA, and a guide RNA (gRNA), a short RNA sequence embedded within a scaffold that directs Cas to its genomic target via sequence complementarity [3]. H11-CAG-hCas mice carry a human codon-optimized Streptococcus pyogenes CRISPR-associated protein 9 (SpCas9) expression cassette, driven by the ubiquitous CAG promoter. This configuration ensures systemic expression of Cas protein across tissues. Notably, constitutive Cas expression in these mice does not elicit detectable toxicity, morphological abnormalities, tumorigenesis, or activation of DNA damage or apoptotic pathways. In the presence of sequence-specific single-guide RNAs (sgRNAs), this model enables efficient and simultaneous editing of single or multiple genes. H11-CAG-hCas mice are viable, fertile, and well-suited for a wide range of genome engineering applications.
Itgax-Dre
Product ID:
C001662
Strain:
C57BL/6JCya
Status:
Live Mouse
Description:
The TGA stop codon was replaced with the "P2A-Dre" cassette. Dre recombinase is expressed under the regulatory control of Itgax gene elements.
The TGA stop codon was replaced with the "P2A-Dre" cassette. Dre recombinase is expressed under the regulatory control of Itgax gene elements.
Kit-LSL-T2A-DTR-P2A-Dre
Product ID:
I001102
Strain:
C57BL/6JCya
Status:
Live Mouse
Description:
The TGA stop codon of the mouse Kit gene is replaced with loxP-6*SV40 pA-loxP-T2A-DTR-P2A-Dre. When Kit-LSL-T2A-DTR-P2A-Dre mice are crossed with Cre mice, the 6*SV40 pA sequence in the offspring mice is deleted, and DTR (diphtheria toxin receptor) and Dre are expressed.
The TGA stop codon of the mouse Kit gene is replaced with loxP-6*SV40 pA-loxP-T2A-DTR-P2A-Dre. When Kit-LSL-T2A-DTR-P2A-Dre mice are crossed with Cre mice, the 6*SV40 pA sequence in the offspring mice is deleted, and DTR (diphtheria toxin receptor) and Dre are expressed.
RC-LR-DTR
Product ID:
I001040
Strain:
C57BL/6JCya
Status:
Live Mouse
Description:
The DTR system is a novel cell lineage ablation system based on the expression of the diphtheria toxin receptor (DTR) in transgenic mice and the administration of diphtheria toxin (DT). By knocking in the DTR gene at the target gene locus (usually a marker gene), selective ablation of cells expressing specific genes can be achieved [1]. When the target gene begins to be expressed in cells of mice that have been transgenically modified to express DTR, injection of DT can induce the death of these cells, resulting in apoptosis. The core of the DTR system is the toxic effect of DT, an exotoxin that, once it enters cells via its receptor, can catalyze the transfer of the ADP-ribosyl moiety from NAD+ to elongation factor 2 (EF-2) due to the ADP-ribosyltransferase activity present in its C-domain, resulting in EF-2 inactivation and inhibition of protein synthesis, ultimately leading to cell death [2]. Due to species differences in the sequence of the DTR gene, the diphtheria toxin receptor in mice cannot bind to DT [3]. This can be overcome by knocking in the primate DTR gene into the mouse genome, allowing specific cells to express DTR and enabling DT to enter specific cells upon administration, and resulting in cell-specific ablation. RC-LR-DTR mice are generated by combining the DTR system with the Cre-loxP and Dre-rox conditional recombinase systems. When these mice are crossed with Cre and Dre mice, DTR can be expressed specifically in tissues to induce tissue- and cell-specific ablation. Heterozygous RC-LR-DTR mice are viable and fertile, and homozygous RC-LR-DTR mice are also viable.
The DTR system is a novel cell lineage ablation system based on the expression of the diphtheria toxin receptor (DTR) in transgenic mice and the administration of diphtheria toxin (DT). By knocking in the DTR gene at the target gene locus (usually a marker gene), selective ablation of cells expressing specific genes can be achieved [1]. When the target gene begins to be expressed in cells of mice that have been transgenically modified to express DTR, injection of DT can induce the death of these cells, resulting in apoptosis. The core of the DTR system is the toxic effect of DT, an exotoxin that, once it enters cells via its receptor, can catalyze the transfer of the ADP-ribosyl moiety from NAD+ to elongation factor 2 (EF-2) due to the ADP-ribosyltransferase activity present in its C-domain, resulting in EF-2 inactivation and inhibition of protein synthesis, ultimately leading to cell death [2]. Due to species differences in the sequence of the DTR gene, the diphtheria toxin receptor in mice cannot bind to DT [3]. This can be overcome by knocking in the primate DTR gene into the mouse genome, allowing specific cells to express DTR and enabling DT to enter specific cells upon administration, and resulting in cell-specific ablation. RC-LR-DTR mice are generated by combining the DTR system with the Cre-loxP and Dre-rox conditional recombinase systems. When these mice are crossed with Cre and Dre mice, DTR can be expressed specifically in tissues to induce tissue- and cell-specific ablation. Heterozygous RC-LR-DTR mice are viable and fertile, and homozygous RC-LR-DTR mice are also viable.
Trhr-Flpo
Product ID:
C001679
Strain:
C57BL/6JCya
Status:
Live Mouse
Description:
The "P2A-Flpo" cassette was inserted upstream of TAA stop codon. Flpo recombinase is expressed under the regulatory control of Trhr gene elements.
The "P2A-Flpo" cassette was inserted upstream of TAA stop codon. Flpo recombinase is expressed under the regulatory control of Trhr gene elements.
Items: 1 to 8 of 8
1
More
All Filters
Strain Type
Mouse
Rat
Modification Type
Knockout
Conditional Knockout
Knockin
Point Mutation
Transgenic
Conditional Knockin
Others
Status
Live Mice
R&D
Frozen Sperm
Validation Data
Verified
In Progress
Reset
Confirm
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Services
HUGO-GT™HUGO-Ab™iPSC Cell LinesAdeno-associated Virus (AAV) Standard Capsid
Drug R&D
NeurologyMetabolicOphthalmologyOncology
About Us
Animal Health & WelfareCorporate OverviewOur TeamHealth Reports
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Global Antibody Drug Industry Development BlueBook (Frost & Sullivan)
Key Insights
The industry is undergoing a rapid transformation driven by next-generation modalities, globalized markets, and upstream technological innovations.
  • Market Structural Shift: Monoclonal antibodies drive steady growth, but ADCs and bispecifics are rapidly accelerating, reshaping the market with higher-value innovations.
  • Chinese Market Globalization: China is actively expanding globally, evidenced by a surge in high-value cross-border license-out deals.
  • Technology-Driven Efficiency: Advanced discovery engines—exemplified by Cyagen's HUGO-Ab platform and AI algorithms—are streamlining candidate screening, optimizing molecular design, and localizing the upstream supply chain.
  • Oncology-Focused Innovation: R&D pipelines remain heavily concentrated on high-incidence malignancies like non-small cell lung cancer, utilizing complex modalities to combat clinical resistance.
Now Available for Download
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research